** Shares of contract drug development company Integer Holdings ITGR.N slump 32.5% to $73.7, set for their worst day on record
** ITGR trims FY 25 rev forecasts to between $1.84 billion and $1.85 billion from the prior range of $1.85 billion-$1.88 billion
** "Select headwinds are expected to impact our 2026 sales" says CEO Joseph Dziedzic
** Q3 adj EPS of $1.79 beats analyst estimates of $1.68- according to data compiled by LSEG
** Nine of 11 brokerages rate the stock "buy" or higher, two "hold"; their median PT is $137.5- LSEG
** Including session's move, ITGR down 47%
(Reporting by Avinash P in Bengaluru)
((Avinash.P@thomsonreuters.com;))